Value of prostatic cancer screening in patients treated for benign prostatic hyperplasia with medical or minimally invasive modalities

Eduardo Orihuela, Jeffrey N. Kocurek, Michael M. Warren

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

OBJECTIVE: To assess the likelihood of overlooking the diagnosis of prostate cancer (PCA), using current screening methods, in patients treated for benign prostatic hyperplasia (BPH) with medical or minimally invasive treatment modalities, which do not produce tissue specimens for histologic review. To appraise this, we examined the impact of the preoperative use of prostatic specific antigen (PSA) in combination with transrectal ultrasound (TRUS) and systematic sextant prostate needle biopsy (PNbx) on the subsequent incidence of stage A PCA in patients undergoing transurethral resection of the prostate (TURP). METHODS/RESULTS: After excluding all patients found to have PCA during pretreatment screening, 485 patients who underwent TURP for presumed BPH from 1976 to 1994, were reviewed. From 1976 to 1989, PSA was not used for pretreatment screening, and stage A PCA was diagnosed in 11.4% of 317 patients. In 1990 and 1991, pretreatment screening included PNbx obtained under ultrasound guidance for PSA ≥ 15.0 ng/ml. Stage A PCA was diagnosed in 14.2% of 63 patients. From 1992 to 1994, pretreatment screening included systematic sextant PNbx performed for PSA > 4.0 ng/ml, and stage A PCA was diagnosed in 2.8% of 105 patients. The difference in incidence of stage A PCA between the first two groups and group three was significant (p=0.021); so is the difference in incidence of stage A2 (p=0.037). For stage A1, the difference did not reach statistical significance (p=0.089). CONCLUSION: Our findings suggest that systematic sextant PNbx for PSA > 4.0 ng/ml significantly reduces the risk of overlooking prostate cancer in patients undergoing treatment of BPH with modalities that do not provide tissue specimens.

Original languageEnglish (US)
Pages (from-to)821-824
Number of pages4
JournalArchivos Espanoles de Urologia
Volume50
Issue number7
StatePublished - Sep 1997

Fingerprint

Prostatic Hyperplasia
Early Detection of Cancer
Prostatic Neoplasms
Antigens
Transurethral Resection of Prostate
Incidence
Needle Biopsy
varespladib methyl
Prostate
Therapeutics

Keywords

  • Benign prostatic hyperplasia
  • Prostate cancer
  • Prostatic specific antigen prostatectomy screening

ASJC Scopus subject areas

  • Urology

Cite this

Value of prostatic cancer screening in patients treated for benign prostatic hyperplasia with medical or minimally invasive modalities. / Orihuela, Eduardo; Kocurek, Jeffrey N.; Warren, Michael M.

In: Archivos Espanoles de Urologia, Vol. 50, No. 7, 09.1997, p. 821-824.

Research output: Contribution to journalArticle

@article{778e494b8a9b4f1c8ef21de6cd020758,
title = "Value of prostatic cancer screening in patients treated for benign prostatic hyperplasia with medical or minimally invasive modalities",
abstract = "OBJECTIVE: To assess the likelihood of overlooking the diagnosis of prostate cancer (PCA), using current screening methods, in patients treated for benign prostatic hyperplasia (BPH) with medical or minimally invasive treatment modalities, which do not produce tissue specimens for histologic review. To appraise this, we examined the impact of the preoperative use of prostatic specific antigen (PSA) in combination with transrectal ultrasound (TRUS) and systematic sextant prostate needle biopsy (PNbx) on the subsequent incidence of stage A PCA in patients undergoing transurethral resection of the prostate (TURP). METHODS/RESULTS: After excluding all patients found to have PCA during pretreatment screening, 485 patients who underwent TURP for presumed BPH from 1976 to 1994, were reviewed. From 1976 to 1989, PSA was not used for pretreatment screening, and stage A PCA was diagnosed in 11.4{\%} of 317 patients. In 1990 and 1991, pretreatment screening included PNbx obtained under ultrasound guidance for PSA ≥ 15.0 ng/ml. Stage A PCA was diagnosed in 14.2{\%} of 63 patients. From 1992 to 1994, pretreatment screening included systematic sextant PNbx performed for PSA > 4.0 ng/ml, and stage A PCA was diagnosed in 2.8{\%} of 105 patients. The difference in incidence of stage A PCA between the first two groups and group three was significant (p=0.021); so is the difference in incidence of stage A2 (p=0.037). For stage A1, the difference did not reach statistical significance (p=0.089). CONCLUSION: Our findings suggest that systematic sextant PNbx for PSA > 4.0 ng/ml significantly reduces the risk of overlooking prostate cancer in patients undergoing treatment of BPH with modalities that do not provide tissue specimens.",
keywords = "Benign prostatic hyperplasia, Prostate cancer, Prostatic specific antigen prostatectomy screening",
author = "Eduardo Orihuela and Kocurek, {Jeffrey N.} and Warren, {Michael M.}",
year = "1997",
month = "9",
language = "English (US)",
volume = "50",
pages = "821--824",
journal = "Archivos Espanoles de Urologia",
issn = "0004-0614",
publisher = "Iniestares, S.A.",
number = "7",

}

TY - JOUR

T1 - Value of prostatic cancer screening in patients treated for benign prostatic hyperplasia with medical or minimally invasive modalities

AU - Orihuela, Eduardo

AU - Kocurek, Jeffrey N.

AU - Warren, Michael M.

PY - 1997/9

Y1 - 1997/9

N2 - OBJECTIVE: To assess the likelihood of overlooking the diagnosis of prostate cancer (PCA), using current screening methods, in patients treated for benign prostatic hyperplasia (BPH) with medical or minimally invasive treatment modalities, which do not produce tissue specimens for histologic review. To appraise this, we examined the impact of the preoperative use of prostatic specific antigen (PSA) in combination with transrectal ultrasound (TRUS) and systematic sextant prostate needle biopsy (PNbx) on the subsequent incidence of stage A PCA in patients undergoing transurethral resection of the prostate (TURP). METHODS/RESULTS: After excluding all patients found to have PCA during pretreatment screening, 485 patients who underwent TURP for presumed BPH from 1976 to 1994, were reviewed. From 1976 to 1989, PSA was not used for pretreatment screening, and stage A PCA was diagnosed in 11.4% of 317 patients. In 1990 and 1991, pretreatment screening included PNbx obtained under ultrasound guidance for PSA ≥ 15.0 ng/ml. Stage A PCA was diagnosed in 14.2% of 63 patients. From 1992 to 1994, pretreatment screening included systematic sextant PNbx performed for PSA > 4.0 ng/ml, and stage A PCA was diagnosed in 2.8% of 105 patients. The difference in incidence of stage A PCA between the first two groups and group three was significant (p=0.021); so is the difference in incidence of stage A2 (p=0.037). For stage A1, the difference did not reach statistical significance (p=0.089). CONCLUSION: Our findings suggest that systematic sextant PNbx for PSA > 4.0 ng/ml significantly reduces the risk of overlooking prostate cancer in patients undergoing treatment of BPH with modalities that do not provide tissue specimens.

AB - OBJECTIVE: To assess the likelihood of overlooking the diagnosis of prostate cancer (PCA), using current screening methods, in patients treated for benign prostatic hyperplasia (BPH) with medical or minimally invasive treatment modalities, which do not produce tissue specimens for histologic review. To appraise this, we examined the impact of the preoperative use of prostatic specific antigen (PSA) in combination with transrectal ultrasound (TRUS) and systematic sextant prostate needle biopsy (PNbx) on the subsequent incidence of stage A PCA in patients undergoing transurethral resection of the prostate (TURP). METHODS/RESULTS: After excluding all patients found to have PCA during pretreatment screening, 485 patients who underwent TURP for presumed BPH from 1976 to 1994, were reviewed. From 1976 to 1989, PSA was not used for pretreatment screening, and stage A PCA was diagnosed in 11.4% of 317 patients. In 1990 and 1991, pretreatment screening included PNbx obtained under ultrasound guidance for PSA ≥ 15.0 ng/ml. Stage A PCA was diagnosed in 14.2% of 63 patients. From 1992 to 1994, pretreatment screening included systematic sextant PNbx performed for PSA > 4.0 ng/ml, and stage A PCA was diagnosed in 2.8% of 105 patients. The difference in incidence of stage A PCA between the first two groups and group three was significant (p=0.021); so is the difference in incidence of stage A2 (p=0.037). For stage A1, the difference did not reach statistical significance (p=0.089). CONCLUSION: Our findings suggest that systematic sextant PNbx for PSA > 4.0 ng/ml significantly reduces the risk of overlooking prostate cancer in patients undergoing treatment of BPH with modalities that do not provide tissue specimens.

KW - Benign prostatic hyperplasia

KW - Prostate cancer

KW - Prostatic specific antigen prostatectomy screening

UR - http://www.scopus.com/inward/record.url?scp=0031231134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031231134&partnerID=8YFLogxK

M3 - Article

C2 - 9350090

AN - SCOPUS:0031231134

VL - 50

SP - 821

EP - 824

JO - Archivos Espanoles de Urologia

JF - Archivos Espanoles de Urologia

SN - 0004-0614

IS - 7

ER -